Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% A Multicentre Randomized Open-label Phase II Trial

NCT07020065 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT07020065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07020065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% A Multicentre Randomized Open-label Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
April 10, 2026
Completion date
September 30, 2030
Enrollment
156 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nsclc - non-small cell lung cancer